E. RISK CHARACTERIZATION

1. Introduction

In this section, the results of the exposure assessment are integrated with the toxicity values identified and derived in the toxicity assessment in order to characterize the hypothetical risks. Investigators identified a total of 64 pesticides and related products (37 active ingredients) as having possibly been used during the Gulf War. Most of these products posed little or no health threat given the combinations of their prevalence, toxicity, and the ways in which they would have almost certainly been handled in the field. Therefore, investigators identified a subset of 15 pesticide formulations known as the pesticides of potential concern (POPCs) for detailed evaluation in the HRA. The 15 POPCs contain 12 different active ingredients.

The noncancer health threat is evaluated by the calculation of a hazard quotient (HQ), where possible, for each POPC, via each route of exposure within each exposure scenario. These HQs are then added together to produce what is known as a hazard index (HI). HIs are presented by scenario/route combination for each active ingredient, and are added together for some combinations of active ingredients to assess potential cumulative effects. Likewise, the cancer risks are determined for each pesticide formulation retained, as appropriate, via each route of exposure within each exposure scenario. The risks are summed to a limited extent to assess cumulative risks.

The chemical-specific HQs and HIs, for the evaluation of noncarcinogenic effects, are presented first, followed by the chemical-specific cancer risks. Next, the potential cumulative hazards and risks are presented. The results for the medium exposure group are the most reliable; the results for the low and high exposure groups are less reliable. Finally, the findings are put into some perspective in the uncertainty and variability analysis at the end of this section.

2. Noncarcinogenic Effects Based on Standard Toxicity Values

Each hazard quotient is calculated as follows:

HQ = Dose/RfD

where,

Dose = appropriate calculated route specific dose
RfD = appropriate route-specific reference dose from the toxicity assessment

For a single chemical, if the HQ > 1, this indicates that the dose exceeds the RfD. The RfD is a conservative value, usually based on animal studies, deliberately set low to be maximally protective of human health in the regulatory setting. Human exposure at or above the RfD, while noteworthy, does not necessarily mean that there will be any real negative impact on human health. Although the higher the actual exposure above the RfD, the greater the likelihood of adverse effects occurring. "Actual" exposure is distinguished from the hypothetical exposures estimated here.

The HQs are then added together in various ways to assess potential combined effects of pesticide active ingredient exposure by calculating hazard indices (HIs). Each chemical-specific and scenario-specific HI is calculated as follows:

HI = HQO + HQD +HQI

where,

HQO = HQ for oral exposure
HQD = HQ for dermal exposure
HQI = HQ for inhalation exposure

An HI for the cumulative effects of multiple concurrent chemical exposures is calculated by adding up appropriate combinations of chemical-specific and scenario-specific HIs, as follows:

HI = HQ1 + HQ2 + … + HQi

where,

HQ1 = HQ for active ingredient Number 1
HQ2 = HQ for active ingredient Number 2
HQi = HQs for all other active ingredients up to the "ith" or last chemical

If the HI > 1, this indicates that the risk-based level of concern is exceeded due to individual and/or cumulative effects.[586] An HQ or HI is a relative measure of the potential to cause adverse noncancer effects; neither HQ nor HI are normally associated with a numerical probability of adverse effects occurring. Additionally, an HQ or HI > 1 does not mean that adverse health effects are guaranteed. Ideally, HQs for multiple chemicals should only be summed for combinations of pesticide active ingredients acting by a similar mechanism, such as cholinesterase inhibition.

Table 106 presents the HQs and scenario-specific HIs for application exposure. In all but one case, the low exposure level HI was well below 1, indicating that adverse health effects would be unlikely for servicemembers in this group. The exception was bendiocarb, with a low exposure HI of 3. About 18% of the medium exposure level HIs exceeded 1, and 75% of the high-exposure HIs exceeded 1. The highest HQs of 1138-1183 are for diazinon EC. In most cases, the high-exposure level is the only level of concern, and relatively few servicemembers would have been exposed at the high level. An important factor that accounts for the dramatic difference between high exposure and medium exposure HIs for ECs and ULV fogs was the use of PPE, assumed by investigators to be appropriate gloves and respirator. Applicators who used appropriate PPE reduced their exposures tremendously.

Diazinon EC and Malathion ULV are associated with the largest contribution to the noncancer hazards for application at the high-exposure level (Table 106); hence, additional discussion of the potential health threat is warranted. About 15% of the PM exposure interviews cited use of diazinon EC. If we assume that a maximum of 4,500 servicemembers were designated as applicators in the KTO, and that the high-exposure level applies to possibly 10% of the applicators who applied diazinon, we conclude that fewer than 70 applicators (4,500 x 0.15 x 0.10) may have been exposed to diazinon EC at the high level. Likewise, fewer than 70 applicators may have been exposed to malathion ULV at the high level.

Table 107 presents the HQs and scenario-specific HIs for post-application exposure. In all but one case, the low exposure level HI was well below 1, indicating that adverse health effects would be unlikely for servicemembers in this group. The exception was dichlorvos, with a low exposure level HI = 12. Only two (14%) medium exposure level HIs exceeded 1, while five (36%) high exposure level HIs exceeded 1.

Dichlorvos may be considered of elevated concern, as the largest number of servicemembers may have received doses exceeding the RfD. According to the RAND survey (Table 11), 7% of ground troops (about 30,530 servicemembers) may have been exposed to dichlorvos, and most of these servicemembers may have had doses above the RfD. The 7% value should be relatively reliable, since the survey was conducted in a scientific manner, and the average veteran would probably remember resin strips fairly well. The HRA determined that even when used at the recommended rate of one resin strip per 1,000 ft3, the RfD would be exceeded at all three exposure levels. The latter finding is in line with a recent EPA human health risk assessment for dichlorvos.[587] The EPA found that all their residential receptor groups exposed to resin strips were exposed above levels of concern (equivalent in this case to inhalation doses well above appropriate RfDs). Additionally, in one respect the HRA may have underestimated the high-exposure HQ for dichlorvos, given that we conducted air modeling based on the label application rate of 1 strip per 1,000 ft3, and some personnel reported in the RAND survey that higher application rates were used.

In contrast to dichlorvos, on the order of 7,000 servicemembers may have had post-application exposure to diazinon at levels exceeding RfDs. The latter estimate is based on 469,047 ground troops, 15% potentially exposed to diazinon EC (from PM interviews) 10% of whom were exposed at the high exposure level. This estimate is rather crude, however, since the 15% overall exposure rate is drawn from the PM interviews, which resulted from highly biased and unscientific sampling, and the 10% value is only a rough estimate. By "biased and unscientific" here, we do not mean that the PM interview data are of poor quality, only that usage rates cannot be extrapolated to the general deployed population with much certainty.

Table 106. Application hazards for evaluation of noncarcinogenic effectsa

Formulation Exp. Level Typed Route-Specific Dosec (mg/kg/d) Hazard Quotiente Scenario Hazard Indexf
Oral Dermald Inhalation Oral Dermald Inhalation
PDRD ADD PDRD ADD
DEET
33% stick/cream
Low - - - - - - - - - -
Med - - - - - - - - - -
High - - - - - - - - - -
DEET 75% liquid Low - - - - - - - - - -
Med - - - - - - - - - -
High - - - - - - - - - -
Permethrin
0.5% aerosol
Low A - 2.20E-03 - 3.53E-06 - 5.11E-05 - 1.41E-05 0.00007
Med S - - 1.03E-04 3.53E-05 - - 9.49E-04 7.06E-04 0.002
High S - - 1.03E-04 3.53E-05 - - 9.49E-04 7.06E-04 0.002
d-Phenothrin
2% aerosol
Low A - - 1.04E-04 3.55E-05 - - 2.09E-03 5.00E-04 0.003
Med S - - 1.04E-04 3.55E-05 - - 2.09E-03 5.00E-04 0.003
High S - - 4.15E-04 1.42E-04 - - 8.36E-03 2.00E-03 0.01
Azamethiphos
1% crystals
Low A - 1.16E-02 - 6.71E-05 - 5.78E-01 - 2.24E-02 0.6
Med S - 2.17E-02 - 1.34E-04 - 1.08E+00 - 4.48E-02

1.1

High C 7.14E-03 - 1.48E-02 2.69E-04 2.86E+00 - 5.90E+00 1.07E-01

9

Methomyl
1% crystals
Low A - 1.16E-02 - 6.71E-05 - 1.28E-02 - 5.16E-04 0.01
Med S - 2.17E-02 - 1.34E-04 - 2.41E-02 - 1.03E-03 0.03
High C 7.14E-03 - 1.48E-02 2.69E-04 8.57E-01 - 1.88E+00 2.07E-03

3

Dichlorvos
20% resin strip
Low - - - - - - - - - -
Med - - - - - - - - - -
High - - - - - - - - - -
Chlorpyrifos 45% liquid (EC) (Handwand) Low A - 2.56E-04 - 1.79E-06 - 5.12E-03 - 1.79E-03 0.007
Med S - - 3.84E-05 8.94E-06 - - 1.42E-01 8.94E-03 0.2
High C - - 7.15E-02 7.15E-04 - - 2.65E+02 2.38E+00

267

Chlorpyrifos 45% liquid (EC) (Backpack) Low A - 1.49E-03 - 1.79E-06 - 2.98E-02 - 1.79E-03 0.03
Med S - - 2.23E-04 8.94E-06 - - 8.27E-01 8.94E-03 0.8
High C - - 7.43E-02 7.15E-04 - - 2.75E+02 2.38E+00

278

Diazinon 48% liquid (EC) (Handwand) Low A - - 4.10E-06 7.15E-07 - - 1.93E-03 8.31E-03 0.01
Med S - - 5.12E-05 8.94E-06 - - 3.01E-01 1.04E-01 0.4
High C - - 1.91E-01 1.43E-03 - - 1.12E+03 1.66E+01

1138

Diazinon 48% liquid (EC) (Backpack) Low A - - 2.38E-05 7.15E-07 - - 1.12E-02 8.31E-03 0.02
Med S - - 2.98E-04 8.94E-06 - - 1.75E+00 1.014E-01 2
High C - - 1.98E-01 1.43E-03 - - 1.17E+03 1.66E+01 1183
Malathion 57% liquid (EC) (Handwand) Low A - 5.12E-04 - 3.57E-06 - 1.02E-03 - 1.28E-05 0.001
Med S - 2.56E-03 - 1.79E-05 - 5.12E-03 - 1.88E-04 0.005
High C - 7.15E+00 - 2.14E-03 - 1.79E+02 - 2.26E-02 179
Malathion 57% liquid (EC) (Backpack) Low

A

-

2.98E-03 - 3.57E-06 - 5.96E-03 - 1.28E-05 0.006
Med

S

-

1.49E-02 - 1.79E-05 - 2.98E-02 - 1.88E-04 0.03
High

C

-

7.43E+00 - 2.14E-03 - 1.86E+02 - 2.26E-02 186
Propoxur 14.7% liquid (EC) (Handwand) Low

A

-

5.12E-04 - 3.57E-06 - 5.12E-05 - 5.69E-07 0.00005
Med

S

-

2.56E-03 - 1.79E-05 - 2.56E-04 - 2.85E-06 0.0003
High

S

-

8.04E+00 - 2.41E-03 - 8.04E-01 - 3.84E-04 0.8
Propoxur 14.7% liquid (EC) (Backpack) Low A - 2.98E-03 - 3.57E-06 - 2.98E-04 - 5.69E-07 0.0003
Med S - 1.49E-02 - 1.79E-05 - 1.49E-03 - 2.85E-06 0.001
High S - 8.36E+00 - 2.41E-03 - 8.36E-01 - 3.84E-04 0.8
Bendiocarb 76% solid (WP) Low A - 3.92E-02 - 4.31E-04 - 2.36E-01 - 2.54E+00 3
Med S - 1.96E-01 - 2.16E-03 - 3.92E+00 - 1.27E+01 17
High S - 5.88E-01 - 6.47E-03 - 1.18E+01 - 3.80E+01 50
Chlorpyrifos
19% liquid (ULV)
Low A - 1.71E-03 - 8.91E-06 - 3.42E-02 - 8.91E-03 0.04
Med S - - 1.02E-04 1.77E-05 - - 3.76E-01 1.77E-02 0.4
High S - - 2.61E-02 3.60E-04 - - 9.67E+01 3.60E-01 97
Malathion
91% liquid (ULV)
Low A - 5.22E-02 - 2.73E-04 - 1.04E-01 - 9.73E-04 0.1
Med S - 1.59E-01 - 8.31E-04 - 3.19E-01 - 8.75E-03 0.3
High C - 4.64E+01 - 1.92E-02 - 1.16E+03 - 2.02E-01 1160
Lindane
1% dust
Low A - - 6.53E-05 6.87E-04 - - 5.48E-03 5.29E-01 0.5
Med S - - 1.58E-03 1.15E-02 - - 1.32E-01 8.86E+00 9
High S 6.86E-02 - 3.81E-02 2.44E-01 1.17E+00 - 3.2E+00 1.88E+02 192
a) In most cases, a dash (-) indicates that the scenario/route combination was inconsequential, and was not evaluated. In cases where at least one dermal dose is provided, the dash indicates that the other dose available is not listed because such dose is unnecessary to calculate the hazard quotient.
b) Exposure type: A = acute/subacute (<2weeks); S = subchronic (2 weeks - 180 days); C = chronic (>180 days). Based on the maximum days exposed.
c) Dose used to calculate hazard quotient (HQ).
d) PDRD = potential dose rate for dermal contact; ADD = absorbed dermal dose.
e) HQ = dose/RfD. HQs are presented for the oral (HQO), dermal (HQD), and inhalation (HQI) routes.
f) Scenario HQ = HQO + HQD + HQI. Greater than 1.0 reflects increased likelihood of adverse health effects.

 

Table 107. Post-application hazards for evaluation of noncarcinogenic effectsa

Formulation Exp. Level Typeb Route-Specific Dosec (mg/kg/d) Hazard Quotiente Scenario Hazard Indexf
Oral Dermald Inhalation Oral Dermald Inhalation
PDRD ADD PDRD ADD
DEET

33% stick/cream

Low A - 2.36E+01 - - - - - - -
Med S - 4.71E+01 - - - - - - -
High C - 1.65E+02 - - - - - - -
DEET

75% liquid

Low A - 5.36E+01 - - - - - - -
Med S - 1.07E+02 - - - - - - -
High C - 3.75E+02 - - - - - - -
Permethrin

0.5% aerosol

Low S - - 1.07E-03 1.94E-03 - - 9.86E-03 3.88E-02 0.05
Med S - - 1.07E-03 2.67E-03 - - 9.86E-03 5.34E-02 0.06
High C - - 1.19E-03 4.74E-03 - - 3.40E-02 1.58E-01 0.2
d-Phenothrin

2% aerosol

Low A - - - 6.50E-06 - - - 9.15E-05 0.00009
Med S - - - 9.61E-06 - - - 1.35E-04 0.00014
High S - - - 1.89E-05 - - - 2.66E-04 0.0003
Azamethiphos

1% crystals

Low - - - - - - - - - -
Med S 4.29E-06 - - - 1.43E-03 - - - 0.001
High C 1.55E-03 - - - 6.20E-01 - - - 0.6
Methomyl

1% crystals

Low - - - - - - - - - -
Med S 4.29E-06 - - - 5.14E-04 - - - 0.0005
High C 1.55E-03 - - 3.47E-02 1.86E-01 - - 2.67E-01 0.5
Dichlorvos

20% resin strip

Low S - - - 6.01E-03 - - - 1.20E+01 12
Med S - - - 3.32E-02 - - - 6.64E+01 66
High S - - - 9.62E-02 - - - 1.92E+02 192
Chlorpyrifos 45% liquid (EC) Low - - - - - - - - - -
Med - - - - - - - - - -
High C - - 2.28E-02 6.97E-05 - - 8.43E+01 2.32E-01 85
Diazinon

48% liquid (EC)

Low - - - - - - - - - -
Med - - - - - - - - - -
High C - - 6.07E-02 8.31E-04 - - 3.57E+02 9.66E+00 367
Malathion

57% liquid (EC)

Low - - - - - - - - - -
Med - - - - - - - - - -
High C - 3.03E+00 - 5.44E-04 - 7.59E+01 - 5.73E-03 76
Propoxur

14.7% liquid (EC)

Low - - - - - - - - -
Med A - 1.52E+00 - 1.06E-05 - 1.52E-01 - 1.69E-06 0.2
High S - 7.05E+00 - 2.11E-04 - 7.05E-01 - 3.36E-05 0.7
Chlorpyrifos

19% liquid (ULV)

Low A - - - 1.03E-04 - - - 1.03E-01 0.1
Med S - - - 1.03E-04 - - - 1.03E-01 0.1
High S - - - 2.09E-04 - - - 2.09E-01 0.2
Malathion

91% liquid (ULV)

Low A - - - 3.28E-03 - - - 1.17E-02 0.01
Med S - - - 3.28E-03 - - - 3.45E-02 0.03
High S - - - 6.65E-03 - - - 7.00E-02 0.07
Lindane

1% dust

Low - - - - - - - - - -
Med - - - - - - - - - -
High - - - - - - - - - -
a) In most cases, a dash (-) indicates that the scenario/route combination was inconsequential, and was not evaluated. In cases where at least one dermal dose is provided, the dash indicates that the other dose available is not listed because such dose is unnecessary to calculate the hazard quotient.
b) Exposure type: A = acute/subacute (<2weeks); S = subchronic (2 weeks - 180 days); C = chronic (>180 days). Based on the maximum days exposed.
c) Dose used to calculate hazard quotient (HQ).
d) PDRD = potential dose rate for dermal contact; ADD = absorbed dermal dose.
e) HQ = dose/RfD. HQs are presented for the oral (HQO), dermal (HQD), and inhalation (HQI) routes.
f) Scenario HI = HQO + HQD + HQI. Greater than 1.0 reflects increased likelihood of adverse health effects.

 

3. Noncarcinogenic Effects Based on Other Human Benchmarks

Detailed information regarding the other human benchmarks (the epidemiological approach) is presented in Tab J; a brief summary of each risk characterization portion is summarized below. If a dose calculated in the exposure assessment (EA) is above a benchmark, this indicates that it may exceed a level of concern. If the EA dose is at or below a benchmark, then it does not exceed the level of concern for the associated endpoint described in Tab J. However, the user should review the details, especially the uncertainty descriptions, in Tab J before drawing conclusions. In most cases, there is significant uncertainty associated with the risk characterizations.

a. DEET

The high-exposure EA dermal doses for DEET slightly exceed the chronic benchmark from the literature, while the low- and medium-exposure values are below the benchmark.

b. Permethrin

The EA dermal and inhalation dose estimates for permethrin are well below the acute/subacute benchmarks for application exposure. Investigators did not identify subchronic or chronic benchmarks, nor benchmarks for post-application exposure.

c. d-Phenothrin

The EA dermal and inhalation dose estimates for permethrin are well below the acute/subacute benchmarks for application exposure. The EA inhalation dose estimates are also well below the acute/subacute benchmarks for post-application exposure. Investigators did not identify subchronic or chronic benchmarks for either application or post-application exposure.

d. Azamethiphos

Investigators were unable to identify useful human benchmarks for azamethiphos in the literature.

e. Methomyl

The EA oral, dermal, and inhalation dose estimates for methomyl are below the benchmarks for application exposure. The EA oral dose estimates are below the benchmark for post-application exposure. The EA high-exposure inhalation dose is slightly above the benchmark for post-application exposure.

f. Dichlorvos

In the dichlorvos post-application inhalation exposure scenarios, the EA-estimated doses were close to the levels at which health effects occurred in the research literature. The low-exposure EA dose is lower than the benchmark, the medium exposure dose is roughly equivalent, and the high-exposure dose is above the benchmark.

g. Chlorpyrifos

Based on the EA/literature comparison for chlorpyrifos EC and ULV application exposure, the EA-calculated route-specific doses are well below the doses at which human health effects occur. This same pattern holds true for the post-application exposure scenarios.

h. Diazinon

The EA low- and medium-exposure dermal dose estimates for diazinon are well below the benchmarks for application exposure. The EA high-exposure dermal doses are higher than the benchmarks. All EA inhalation doses are below benchmarks. The high-exposure EA dermal dose exceeds the benchmark, while the high-exposure EA inhalation dose is well below the benchmark.

i. Malathion

The EA low- and medium-exposure dermal dose estimates for malathion EC and ULV are well below the benchmark for application exposure; while the high-exposure doses exceed this benchmark. All EA inhalation doses are well below the benchmark for application exposure. The EA high-exposure dermal dose estimate exceeds the benchmark for post-application exposure, while the EA high-exposure inhalation dose is well below the benchmark.

j. Propoxur

All EA-estimated doses for relevant scenarios and exposure routes are well below the available benchmarks for both application and post-application exposure.

k. Bendiocarb

The EA-estimated low-exposure dermal dose for application exposure is below the benchmark, while the medium- and high-exposure doses are above the benchmark. All EA-estimated inhalation doses for application exposure are well below the benchmark. The EA-estimated medium- and high-exposure dermal doses for post-application exposure exceed the benchmark.

l. Lindane

The EA-estimated oral and inhalation doses for application exposure are below the benchmarks. Investigators did not identify appropriate benchmarks for dermal exposure.

4. Carcinogenic Effects

Investigators assessed potential carcinogenic effects by calculating a risk (probability) of excess cancer development associated with each relevant pesticide formulation retained, via each route of exposure, based on the medium exposure level, where available, or high exposure level if not. These route-specific risks have also been summed for each POPC for all three routes of exposure within each scenario.

The risk characterization for cancer is determined somewhat differently than that for noncancer effects as there are no specific thresholds for adverse effects. Thus, the following risk range benchmarks have been used here to establish the significance of risk:

These benchmarks were established by analogy with those used by the EPA[588] for many years, although the EPA does not explicitly refer to "significance" in this context. The EPA typically uses these benchmarks in risk management programs throughout the Agency. Normally risks below 1E-06 are considered negligible. Risks between 1E-06 to 1E-04 are frequently, but not always, taken to be "acceptable." Risks greater than 1E-04 typically pose an elevated level of concern.

The route-specific risks and summed scenario-specific risks for application exposure are presented in Table 108. There are relatively few values presented in Table 108 mainly because few of the pesticide active ingredients are associated with carcinogenic effects via the exposure routes of interest, and because only the medium-exposure scenarios are evaluated per OPP guidance (Tab D, Section D, "Toxicity Assessment").

Table 108. Application risks for evaluation of carcinogenic effects

Formulation Exposure Level

Route-Specific LADDa (mg/kg/d)

Riskb (mg/kg/d)-1

Combination
Scenario Risk
c

Oral Dermal Inhalation Oral Dermal Inhalation
DEET
33% stick/cream

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
DEET
75% liquid

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Permethrin
0.5% aerosol

Low

- - - - - - 1.84E-09

Med

- 6.46E-08 2.21E-08 - 1.49E-09 3.54E-10

High

- - - - - -
d-Phenothrin
2% aerosol

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Azamethiphos
1% crystals

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Methomyl
1% crystals

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Dichlorvos
20% resin strip

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Chlorpyrifos 45% liquid (EC) (Handwand Sprayer)

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Chlorpyrifos 45% liquid (EC) (Backpack Sprayer)

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Diazinon 48% liquid (EC) (Handwand Sprayer)

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Diazinon 48% liquid (EC) (Backpack Sprayer)

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Malathion 57% liquid (EC) (Handwand Sprayer)

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Malathion 57% liquid (EC) (Backpack Sprayer)

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Propoxur 14.7% liquid (EC) (Handwand Sprayer)

Low

- - - - - - 1.05E-09

Med

- 2.57E-07 1.12E-08 - 1.01E-09 4.14E-11

High

- - - - - -
Propoxur 14.7% liquid (EC) (Backpack Sprayer)

Low

- - - - - - 5.91E-09

Med

- 1.49E-06 1.12E-08 - 5.87E-09 4.14E-11

High

- - - - - -
Bendiocarb
76% solid (WP)

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Chlorpyrifos
19% liquid (ULV)

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Malathion
91% liquid (ULV)

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Lindane
1% dust

Low

- - - - - - 2.84E-04

Med

- - - - 2.22E-06 1.61E-05

High

- - - 2.66E-04 - -
a) LADD = lifetime average daily dose. A dash (-) indicates that a LADD was not calculated, for one or both of two reasons. First, LADDs were only calculated for chemicals having slope factors. Second, LADDs were calculated for the medium exposure level only, if possible; otherwise, the high exposure level was used. Most of the active ingredients listed are not associated with carcinogenic activity.
b) Risk = LADD x slope factor. Risks are presented for the oral (risko), dermal (riskd), and inhalation (riski) routes.
c) Combination scenario risk = risko + riskd + riski. Addends are drawn from low, medium, or high exposure levels, as available.

These findings do not demonstrate that any veteran has or will develop cancer as a result of delousing. According to our investigation, roughly 200 servicemembers were engaged in delousing of EPWs. Based on this, the excess cancer risk for lindane of 3 x 10-4 translates to not even one excess cancer for this group (200 x 3 x 10-4 = 0.06 excess cancers).

The route-specific risks and summed scenario-specific risks for post-application exposure are presented in Table 109. There are no significant risks for post-application exposure. There are relatively few values presented in Table 109 for the same reasons described for Table 108.

Table 109. Post-application risks for evaluation of carcinogenic effects

Formulation

Exposure Level

Route-Specific LADDa (mg/kg/d)

Riskb (mg/kg/d) -1

Combination
Scenario Risk
c

Oral Dermal Inhalation Oral Dermal Inhalation
DEET
33% stick/cream

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
DEET
75% liquid

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Permethrin
0.5% aerosol

Low

- - - - - - 2.49E-07

Med

- 5.03E-06 8.36E-06 - 1.16E-07 1.34E-07

High

- - - - - -
d-Phenothrin
2% aerosol

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Azamethiphos
1% crystals

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Methomyl
1% crystals

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Dichlorvos
20% resin strip

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Chlorpyrifos
45% liquid (EC)

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Diazinon
48% liquid (EC)

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Malathion
57% liquid (EC)

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Propoxur
14.7% liquid (EC)

Low

- - - - - - 4.49E-07

Med

- 1.14E-04 4.96E-09 - 4.49E-07 1.84E-11

High

- - - - - -
Bendiocarb
76% solid (WP)

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Chlorpyrifos
19% liquid (ULV)

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Malathion
91% liquid (ULV)

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
Lindane
1% dust

Low

- - - - - - -

Med

- - - - - -

High

- - - - - -
a) LADD = lifetime average daily dose. A dash (-) indicates that a LADD was not calculated, for one or both of two reasons. First, LADDs were only calculated for chemicals having slope factors. Second, LADDs were calculated for the medium exposure level only, if possible; otherwise, the high exposure level was used. Most of the active ingredients listed are not associated with carcinogenic activity.
b) Risk = LADD x slope factor. Risks are presented for the oral (risko), dermal (riskd), and inhalation (riski) routes.
c) Combination scenario risk = risko + riskd + riski. Addends are drawn from low, medium, or high exposure levels, as available.



5. Cumulative Hazards and Risks

Tables 110 and 111 present the representative hazard indices (HIs) by branch of service, and the cumulative HIs for organophosphates and carbamates combined. Table 110 presents values for post-application exposure, while Table 111 presents values for applicators (application and post-application exposure). The phrase, "representative hazard index," as used here, means an HI that is potentially relevant to the most servicemembers within each major exposure subdivision (post-application or application). Probably well below 7% of servicemembers who served on the ground in the KTO might have been associated with cumulative HIs for OPs and carbamate approaching those presented in Table 110, and less than 0.2% might have been associated with total HIs for OPs and carbamate approaching those presented in Table 111. Cumulative HIs were compiled as follows:

The criteria for grouping pesticides are fairly straightforward. For post-application exposure, the only difference among the branches has to do with ECs and bendiocarb. The Army did not use much bendiocarb, while the Navy (including Marines) and Air Force did. Since the medium HI for bendiocarb is higher than that for ECs, it was used to represent exposure for the Navy and Air Force in lieu of an EC HI. Conversely, the HI for propoxur was used for the Army in lieu of a bendiocarb HI. Propoxur had the highest medium HI of the ECs. All branches were assumed to be exposed to DEET, permethrin, d-phenothrin, azamethiphos, and dichlorvos. The medium HI for azamethiphos is higher than that for methomyl.

For applicators, the differences have to do with ECs, bendiocarb, and post-application exposure. Again, the bendiocarb medium HI was used for the Navy and Air Force, while an EC medium HI was used for the Army. The EC in the latter case was diazinon, as the HI was higher than for the other ECs. Since applicators would have also experienced post-application exposure similar to non-applicators, post-application exposure is added in.

The rationale for grouping OP and carbamate pesticide formulations together is fully supported by a large body of literature, spanning decades, documenting a common mechanism of action: inhibition of cholinesterase. Details regarding the common mechanism of action are available in many sources, including the RAND pesticides literature review,[589] Ecobichon, [590] Karczmar[591] Furthermore, draft policy at EPA's Office of Pesticide Programs (OPP) groups the OPs and carbamates together, and describes the rationale in detail.[592]

The cumulative HIs presented in Table 111 are higher than the comparable values in Table 110, but are potentially relevant mainly to a small subset of servicemembers who applied specific pesticide formulations, such as ECs and bendiocarb WP.

The cumulative HIs listed for OPs and carbamates all exceed one, and are therefore presumed by investigators to indicate that veterans may have been exposed to levels of pesticide active ingredients capable of causing an identifiable physiological response such as the suppression of plasma cholinesterase. The fact that the HIs not only exceed 1, but significantly exceed one, indicates a relatively greater potential for such a response than if the HIs were closer to or below one. The HIs for lindane are small in comparison to the cumulative HIs shown for OPs and carbamate, and the HIs for permethrin and d-phenothrin, well below one, are relatively insignificant.

Cumulative cancer risks were not calculated because it was unnecessary.

Table 110. Cumulative hazard indicies for post-application exposure

Pesticide Group

Formulation

Representative Hazard Indexa
Army Navy Air Force

Repellent (skin)

DEET, 33% stick/cream

Negligible

Negligible

Negligible
DEET, 75% liquid
Repellent (clothing) Permethrin, 0.5% aerosol 0.06 0.06 0.06
Area Spray d-Phenothrin, 2% aerosol 0.00014 0.00014 0.00014
Organophosphate/Carbamate Azamethiphos, 1% 0.001 0.001 0.001
Dichlorvos, 20% resin strip 66 66 66
Propoxur, 14.7% liquid (EC) 0.2 - -
Bendiocarb, 76% solid (WP) - 8 8
Chlorpyrifos, 19% liquid (ULV) 0.1 0.1 0.1
Cumulative for OP/Carbamate 67 74 74
a) Based on selected medium scenario-specific HIs. The highest medium HI was selected for each pesticide formulation subgroup (EC/WP or ULV) as representative, based on appropriateness to branch of service. An HI greater than 1.0 reflects increased likelihood of adverse health effects. A dash (-) indicates that either the pesticide formulation was used by 5% or fewer personnel, or that another listed pesticide from the same pesticide formulation subgroup was selected as representative because it was used more frequently and/or had a higher medium HI.

 

Table 111. Cumulative hazard indicies for applicator personnel

Pesticide Group

Formulation

Representative Hazard Indexa
Army Navy Air Force

Repellent (skin)

DEET, 33% stick/cream

Negligible

Negligible

Negligible
DEET, 75% liquid
Repellent (clothing) Permethrin, 0.5% aerosol 0.06 0.06 0.06
Area Spray d-Phenothrin, 2% aerosol 0.003 0.003 0.003
Lindane Dust Lindane, 5% dust 9 9 9
Organophosphate/Carbamate Azamethiphos, 1% 1.1 1.1 1.1
Diazinon, 48% liquid (EC) 2 - -
Bendiocarb, 76% solid (WP) - 17 17
Chlorpyrifos, 19% liquid (ULV) 0.4 0.4 0.4
Post-Application Exposure 67 74 74
Cumulative for OP/Carbamate 71 93 93
a) Based on selected medium scenario-specific HIs. The highest medium HI was selected for each pesticide formulation subgroup (EC/WP or ULV) as representative based on appropriateness to branch of service. For permethrin and d-phenothrin, the HI listed is the application plus post-application HI. An HI greater than 1.0 reflects increased likelihood of adverse health effects. A dash (-) indicates that either the pesticide formulation was used by 5% or fewer personnel, or that another listed pesticide formulation from the same formulation subgroup was selected as representative because it was used more frequently and/or had a higher medium HI.

| First Page | Prev Page | Next Page |